Business Development (2)

Challenge: An oncology company with a ‘hub and spoke’ structure wished to commission an expert third-party due diligence on one of its spin-out companies in support of its next investment round. The...

Challenge: Our client was a pharmaceutical company considering an acquisition of two approved assets and required expert due diligence on the clinical, regulatory and manufacturing aspects of the two...

Challenge: An early-stage biotechnology company with several assets in pre-clinical development for CNS diseases wanted to supplement its internal pipeline with external innovation. The company...

Challenge: A biotechnology company with clinical-stage assets positioned in several neuropsychiatric disorders wanted to supplement its internal pipeline with external innovation. The company wanted...

Challenge: A VC firm was exploring investment in a spin-out company with an antibody targeted at metastatic cancer indications. Before committing to the financing round, the investor required...

Challenge: A private investment firm was interested in a European drug re-purposing company and asked Alacrita to perform top-level due diligence to help the firm decide whether it wanted to proceed...

Challenge: Our client, a mid-cap pharma, was planning to extend its portfolio in the gastrointestinal (GI) disease space. It was considering microbiome-based approaches, specifically live...

Challenge: A lean pharma company reached out to Alacrita for due diligence support regarding three oncology assets of interest, prior to entering into licensing negotiations. The client requested an...

Challenge: A leading NK cell research group had developed a novel process for manufacturing NK cells with highly differentiated properties. The technology had been licensed to a start-up company that...

Challenge: A late pre-clinical biotech company engaged in the development of antibody drug conjugates (ADCs) targeting GPCRs for treatment of solid tumors asked Alacrita to conduct an internal due...

Challenge A recently emerged biotech company developing prophylactic monoclonal antibodies (mAbs) against a major viral target for immunocompromised patients asked Alacrita to develop an independent...

Challenge A UK-based oncology drug development company was planning to in license a small molecule in development for hepatocellular carcinoma (HCC) and Rhabdomyosarcoma. Alacrita was commissioned to...